SCHEMBL754071

SCHEMBL754071

COc1cccc(OC)c1C1NC(=O)C(C)(C)O1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 2/20 0.36
LMNA P02545 2/20 0.36
ACHE P22303 1/20 0.36
NQO1 P15559 1/20 0.35
POR P16435 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
KMT2A Q03164 4/20 0.34
MEN1 O00255 3/20 0.34
CYP2A6 P11509 2/20 0.34
GAA P10253 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
CREBBP Q92793 1/20 0.34
HPGD P15428 1/20 0.33
POLB P06746 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL752976 0.90 KDM4E (0.40) ALDH1A1KDM4ELMNAACHEKMT2A
SCHEMBL753078 0.87 SIRT2 (0.44) ALDH1A1KMT2AMEN1HSD17B10TDP1
SCHEMBL749617 0.70 L3MBTL1 (0.40) ALDH1A1KDM4ELMNAACHECRHBP
SCHEMBL752251 0.70 TCF4 (0.38) ALDH1A1KDM4ELMNAACHEKMT2A
SCHEMBL752648 0.70 TCF4 (0.38) ALDH1A1KDM4ELMNAACHEKMT2A
SCHEMBL752252 0.70 TCF4 (0.38) ALDH1A1KDM4ELMNAACHEKMT2A
SCHEMBL27864097 0.69 TLR2 (0.33) ALDH1A1KDM4ELMNANQO1POR
SCHEMBL4535855 0.64 ALDH1A1 (0.42) ALDH1A1LMNAACHECRHBPCRHR2
SCHEMBL29669626 0.64 IRAK4 (0.44) ALDH1A1KDM4EACHECRHBPCRHR2
SCHEMBL5732983 0.64 CREBBP (0.46) ALDH1A1KDM4ELMNAACHEKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430004-B1 NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2013-07-17 EP disclosed
US-8329706-B2 Oxazolidinone derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-12-11 US disclosed
US-20120101111-A1 NOVEL OXAZOLIDINONE DERIVIATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2012-04-26 US disclosed
EP-2430004-A2 NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-03-21 EP disclosed
WO-2010131192-A2 NOVEL OXAZOLIDINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101111-A1 NOVEL OXAZOLIDINONE DERIVIATIVES HCRTR2, HCRTR1, NPY4R ALDH1A1 715/4885KDM4E 1180/4885LMNA 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.